

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, C07D 401/00	A1	(11) International Publication Number: WO 98/22109 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21020 (22) International Filing Date: 17 November 1997 (17.11.97) (30) Priority Data: 60/031,466 20 November 1996 (20.11.96) US 9700540.9 13 January 1997 (13.01.97) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): CHANG, Linda, L. [CA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Agent: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS (57) Abstract 2,4-Diaryl-5-pyridylimidazoles are glucagon antagonists. The compounds block the action of glucagon at its receptor. Thus, the compounds can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon. Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

TITLE OF THE INVENTIONTRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON
ANTAGONISTS5 BACKGROUND OF THE INVENTION

The present invention relates to triaryl substituted imidazoles which antagonize the metabolic effect of glucagon. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.

10 Diabetes is a disease process derived from multiple causative factors and characterized by elevated levels of plasma glucose. Uncontrolled hyperglycemia is associated with an increased risk for microvascular and macrovascular diseases, including nephropathy, retinopathy, hypertension, stroke and heart disease. Control of glucose
15 homeostasis is, therefore, a major approach to the treatment of diabetes.

Glucagon is a major counter regulatory hormone that attenuates the inhibition of liver gluconeogenesis by insulin. Glucagon receptors are found primarily in the liver, although their presence has been documented in kidney, pancreas, adipose tissues, heart, smooth
20 muscles of vascular tissues, and some regions of the brain, stomach and adrenal glands.

Type II diabetics have elevated levels of plasma glucagon and increased rates of hepatic glucose production. The rate of hepatic glucose production positively correlates with fasting blood glucose levels
25 in type II diabetics. Therefore, antagonists of glucagon are useful in improving insulin responsiveness in the liver, decreasing the rate of gluconeogenesis and lowering the rate of hepatic glucose output resulting in a decrease in the levels of plasma glucose.

A monoclonal antibody to glucagon (Glu-mAb) has been
30 utilized to test the acute effects of attenuation of glucagon action in streptozotocin-treated diabetic rats (Brand et al., Diabetologia 37:985, 1994). In contrast to a control antibody, injection of Glu-mAb attenuated the postprandial increase in blood glucose in moderately hyperglycemic rats (ie., rats with a moderate impairment in insulin secretion). In

- 2 -

severely hyperglycemic rats (ie., rats with severely impaired insulin secretion), Glu-mAb injection did not lower blood glucose levels, but potentiated the hypoglycemic effect of a suboptimal dose of insulin. These data suggest that attenuation of the action of glucagon in these
5 models leads to increased sensitivity to the action of insulin, but does not lead to decreased blood glucose levels in the absence of insulin. On the other hand, a monoclonal antibody to glucagon was effective in lowering plasma glucose levels in diabetic rabbits independent of insulin effects (Brand et al., *Diabetes*, 45:1076 (1996)). While these data support the
10 notion that antagonism of glucagon action will provide beneficial therapy for both type I and type II diabetics, this hypothesis could be more rigorously tested if a specific non-peptidyl glucagon antagonist were available.

The regulation of glucagon homeostasis is also mediated by
15 the hormone insulin, produced in the β cells of the pancreas. Deterioration of these cells is typically observed in Type I diabetics, and abnormalities in the function of these cells may occur in patients presenting the symptoms of Type II diabetes. Thus, a glucagon antagonist might have utility in treating Type I diabetics.

20 The glucagon receptor is expressed in kidney tissues where glucagon has been demonstrated to have an effect on electrolyte homeostasis including the ions sodium, potassium, chloride, magnesium, calcium, and phosphate and the non-electrolytes urea and water (Ahloulay et al., *Am. J. Physiol.*, 269: F225, 1995). A glucagon
25 antagonist may have use in treating disorders involving electrolyte imbalance. The kidney is also gluconeogenic in response to glucagon (Amores et al., *Molec. Cell. Biochem.*, 137: 117, 1994) and an antagonist would act to lower glucose production in kidney furthering the treatment of diabetes.

30 Glucagon receptors are present in the heart and in smooth muscles. Glucagon has a direct effect on cardiac output and heart rate (Glick et al., *Circ. Res.*, 22: 789 (1968); Farah, *Pharm. Rev.*, 35: 181, 1983). A strong correlation has been observed in patients with hypertension and elevated plasma glucagon levels resulting from

- 3 -

impaired hepatic catabolism (Silva et al., *Hepatology*, 11: 668, 1990). Antagonism of the effects of elevated glucagon levels may have an effect on certain types of hypertension, thus a glucagon antagonist may have utility in the treatment of certain types of hypertension associated
5 with elevated glucagon production.

The primary role for glucagon and glucagon receptors associated with adipose tissues is to induce lipolysis, thus providing free fatty acids as a substrate for fat burning tissues (Saggerson et al., *Biochem. J.*, 238: 387, 1986). An antagonist to this effect might be useful
10 in treating conditions where there is excessive lipolysis of fat stores resulting from elevated glucagon levels, such as wasting disease (cachexia).

Glucagon and glucagon receptors have been localized to the hippocampus region of the brain (Hoosein and Gurd, *Proc. Natl. Acad. Sci. USA*, 81: 4368, 1984). This discovery suggests that glucagon may have a neuroendocrine role in initiating or elaborating basic behavior or somatic motor programs. Since glucagon secretion is increased in response to low blood glucose levels, increased glucagon levels in the brain may initiate behavior to respond to low glucose levels, such as
20 eating. Thus, chronic hyperglucagonemia may also result in a constant craving for food resulting in obesity. A glucagon antagonist may have utility in treating obesity by altering feeding behavior associated with a response to glucagon.

The compounds in the present invention are glucagon
25 antagonists. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant compounds thus are useful as antidiabetic agents. Glucagon may have other direct effects on cardiac output, lipolysis, and feeding behavior and therefore may be useful as antihypertensive, anti-cachexia or antiobesity
30 agents.

SUMMARY OF THE INVENTION

The present invention relates to 2,4-diaryl-5-pyridyl imidazoles which are glucagon receptor antagonists. These compounds

- 4 -


are therefore useful for the treatment of diseases caused by excessive levels of glucagon, including diabetes and certain types of hypertension, cachexia and obesity.

Also included in the invention are pharmaceutical compositions which comprise a compound of formula I in combination with a pharmaceutically acceptable carrier.

Also included in the invention are methods of treating glucagon-mediated disease, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective to treat said disease.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds of formula (I):



wherein

R₁ is 4-pyridyl, 4-pyrimidinyl or 4-quinolyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- (1) halogen,
- (2) -CN,
- (3) C₁-10 alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (4) -O-C₁-10 alkyl,
- (5) -S-C₁-10 alkyl,
- (6) -NR₈R₉, and
- (7) -NO₂;

- 5 -

R₂ is phenyl, 1-naphthyl, 2-naphthyl or heteroaryl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of

- 5
- (1) C₁₋₁₀ alkyl,
 - (2) R₄, and
 - (3) C₁₋₁₀ alkyl substituted with up to 5 groups independently selected from R₄;

R₃ is phenyl, which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- 10
- (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (2) -O-C₃₋₁₀ alkyl,
 - (3) -O-C₁₋₄ alkylaryl,
 - 15 (4) -S-C₂₋₁₀ alkyl,
 - (5) -S(O)_mC₃₋₁₀ alkyl,
 - (6) -C(O)C₃₋₁₀ alkyl,
 - (7) -CO₂C₃₋₁₀ alkyl,
 - (8) -NR₇R₁₇,
 - 20 (9) *meta* -O-phenyl, which is optionally substituted with halo, C₁₋₄ alkyl, or C₁₋₄ alkoxy;

R₄ is

- (1) -OR₈,
- (2) -NO₂,
- 25 (3) halogen
- (4) -S(O)_mR₁₁,
- (5) -SR₈,
- (6) -S(O)_mOR₈,
- (7) -S(O)_mNR₈R₉,
- 30 (8) -NR₈R₉,
- (9) -O(CR₁₀R₂₀)_pNR₈R₉,
- (10) -C(O)R₈,
- (11) -CO₂R₈,
- (12) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,

- 6 -

- (13) -ZC(O)R₈,
 (14) -CN,
 (15) -C(Z)NR₈R₉,
 (16) NR₁₀C(Z)R₈,
 5 (17) -C(Z)NR₈OR₉,
 (18) NR₁₀C(Z)NR₈R₉,
 (19) -NR₁₀S(O)_mR₁₁,
 (20) -C(=NOR₂₁)R₈,
 (21) -NR₁₀C(=NR₁₅)SR₁₁,
 10 (22) -NR₁₀C(=NR₁₅)NR₈R₉,
 (23) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
 (24) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,
 (25) -NR₁₀C(O)C(O)NR₈R₉,
 (26) -NR₁₀C(O)C(O)OR₁₀,
 15 (27) -C(=NR₁₃)NR₈R₉,
 (28) -C(=NOR₁₃)NR₈R₉,
 (29) -C(=NR₁₃)ZR₁₁,
 (30) -OC(Z)NR₈R₉,
 (31) -NR₁₀S(O)_mCF₃,
 20 (32) -NR₁₀C(Z)OR₁₀,
 (33) 5-(R₁₈)-1,2,4-oxadiazol-3-yl or
 (34) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl;

R₇ and R₁₇ are each independently selected from hydrogen or C₁₋₄ alkyl
 provided that R₇ and R₁₇ are not both hydrogen; or R₇ and R₁₇
 25 together with the nitrogen to which they are attached form a
 heterocyclic ring of 5 to 7 members which ring optionally
 contains an additional heteroatom selected from oxygen, sulfur or
 NR₂₂;

R₈ and R₉ are independently selected from

- 30 (1) hydrogen,
 (2) heterocyclyl,
 (3) heterocyclyl-C₁₋₁₀ alkyl, and
 (4) R₁₁; or

- 7 -

- R8 and R9 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR₁₂;
- 5 R₁₀ and R₂₀ is each independently selected from hydrogen or C₁₋₄ alkyl;
- R₁₁ is
- (1) C₁₋₁₀ alkyl,
 - (2) halo-substituted C₁₋₁₀ alkyl,
 - (3) C₂₋₁₀ alkenyl,
 - (4) C₂₋₁₀ alkynyl,
 - 10 (5) C₃₋₇ cycloalkyl,
 - (6) C₅₋₇ cycloalkenyl,
 - (7) aryl,
 - (8) aryl-C₁₋₁₀ alkyl,
 - (9) heteroaryl or
 - 15 (10) heteroaryl-C₁₋₁₀ alkyl;
- R₁₂ is
- (1) hydrogen,
 - (2) -C(Z)R₁₃,
 - (3) optionally substituted C₁₋₁₀ alkyl, wherein the substituents may be halo, C₁₋₃ alkoxy, amino, or carboxy,
 - 20 (4) optionally substituted aryl C₁₋₁₀ alkyl, wherein the substituents may be halo, C₁₋₃ alkoxy, amino, or carboxy, or
 - (5) S(O)₂R₂₅;
- R₁₃ is
- (1) hydrogen, or
 - (2) R₂₅;
- 25 R₁₄ and R₂₄ is each independently selected from
- (1) hydrogen,
 - (2) C₁₋₄ alkyl,
 - (3) nitro or
 - (4) cyano;
- 30 R₁₅ is
- (1) hydrogen,
 - (2) cyano,
 - (3) C₁₋₄ alkyl,
 - (4) C₃₋₇ cycloalkyl or
 - (5) aryl;

- 8 -

R₁₈ and R₁₉ is each independently selected from

- (1) hydrogen,
- (2) C₁₋₄ alkyl,
- (3) substituted C₁₋₄ alkyl, wherein the substituents may be
5 halo, C₁₋₃ alkoxy, amino, or carboxy,
- (4) optionally substituted aryl, wherein the substituents may
be halo, C₁₋₃ alkoxy, amino, or carboxy,
- (5) optionally substituted aryl-C₁₋₁₀ alkyl, wherein the
substituents may be halo, C₁₋₃ alkoxy, amino, or carboxy, or

10 R₁₈ and R₁₉ together denote an oxo or thioxo;

- R₂₁ is
- (1) R₁₃,
 - (2) a pharmaceutically acceptable cation, or
 - (3) aroyl, or
 - (4) C₁₋₁₀ alkanoyl;

15 R₂₂ is R₁₀ or C(Z)-C₁₋₄ alkyl;

- R₂₅ is
- (1) C₁₋₁₀ alkyl,
 - (2) C₃₋₇ cycloalkyl,
 - (3) heterocyclyl,
 - (4) aryl,
 - 20 (5) aryl C₁₋₁₀ alkyl,
 - (6) heterocyclyl-C₁₋₁₀ alkyl,
 - (7) heteroaryl or
 - (8) heteroaryl C₁₋₁₀ alkyl;

Z is oxygen or sulfur;

25 m is 1 or 2;

n is 1 to 10;

p is 1 to 10; or

a pharmaceutically acceptable salt thereof.

In one subset of the present compounds, there are provided
30 compounds of formula (I) wherein

R₁ is 4-pyridyl which is unsubstituted or substituted with one or two
substituents each of which is independently selected from the
group consisting of

- (1) halogen,

- 9 -

- 5
- (2) -CN,
 - (3) C₁₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (4) -O-C₁₋₁₀ alkyl,
 - (5) -S-C₁₋₁₀ alkyl,
 - (6) -NR₈R₉, and
 - (7) -NO₂.

In a further subset of the present compounds, there are provided compounds of formula (I) wherein

10 R₂ is phenyl, 1-naphthyl or 2-naphthyl each of which is unsubstituted or substituted with one, two or three groups each of which is independently selected from the group consisting of

- (1) C₁₋₁₀ alkyl,
- (2) R₄, and
- 15 (3) C₁₋₁₀ alkyl substituted with up to 5 groups independently selected from R₄.

Another subset of the present compounds provides compounds of formula (I) wherein

20 R₃ is phenyl, which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (2) -O-C₃₋₁₀ alkyl,
- 25 (3) -O-C₁₋₄ alkylaryl,
- (4) -S-C₂₋₁₀ alkyl,
- (5) *meta* -O-phenyl, which is optionally substituted with halo, C₁₋₄ alkyl, or C₁₋₄ alkoxy;

In a preferred embodiment there are provided compounds of

30 formula (I) wherein

R₁ is 4-pyridyl or 4-quinolyl;

R₂ is phenyl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of

- 10 -

- (1) C₁₋₁₀ alkyl,
 - (2) R₄, and
 - (3) C₁₋₁₀ alkyl substituted with up to 5 groups independently selected from R₄;
- 5 R₃ is phenyl substituted with one or two substituents each of which is independently selected from the group consisting of
- (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (2) -O-C₃₋₁₀ alkyl,
 - 10 (3) -O-C₁₋₂ alkylaryl,
 - (4) -S-C₂₋₁₀ alkyl,
 - (5) *meta* -O-phenyl, which is optionally substituted with halo, C₁₋₄ alkyl, or C₁₋₄ alkoxy;
- R₄ is
- 15 (1) -OR₈,
 - (2) halogen.
- R₈ is selected from
- (1) hydrogen, and
 - (2) R₁₁; and
- 20 R₁₁ is
- (1) C₁₋₁₀ alkyl,
 - (2) halo-substituted C₁₋₁₀ alkyl,
 - (3) C₃₋₇ cycloalkyl,
 - (4) aryl,
 - (5) aryl-C₁₋₁₀ alkyl, or
- 25 a pharmaceutically acceptable salt thereof.
- In a further preferred embodiment there are provided compounds of formula (I) wherein
- R₁ is 4-pyridyl;
- R₂ is phenyl which is substituted with one or two substituents each of which is
- 30 independently selected from the group consisting of
- (1) C₁₋₁₀ alkyl,
 - (2) R₄, and
 - (3) C₁₋₁₀ alkyl substituted with up to 5 groups independently selected from halogen


- 11 -

- R₃ is phenyl substituted with one or two substituents each of which is independently selected from the group consisting of
- (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (2) -O-C₃₋₁₀ alkyl,
 - (3) -O-C₁₋₂ alkylaryl,
 - (4) -S-C₂₋₁₀ alkyl,
 - (5) *meta* -O-phenyl, which is optionally substituted with halo, C₁₋₄ alkyl, or C₁₋₄ alkoxy;
- R₄ is
- (1) -OR₈,
 - (2) halogen;
- R₈ is R₁₁;
- R₁₁ is
- (1) C₁₋₁₀ alkyl,
 - (2) halo-substituted C₁₋₁₀ alkyl,
 - (3) C₃₋₇ cycloalkyl,
 - (4) aryl,
 - (5) aryl-C₁₋₁₀ alkyl, or
- a pharmaceutically acceptable salt thereof.
- Especially preferred compounds of formula I include:
- (1) 2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
 - (2) 2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
 - (3) 2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
 - (4) 2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
 - (5) 4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole
 - (6) 4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole
 - (7) 4-(4-t-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole

- 12 -

- 5
- (8) 4-(4-t-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole
- (9) 2-(4-chlorophenyl)-4-(4-n-propyloxyphenyl)-5-(4-pyridyl)imidazole
- 10
- (10) 2-(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4-pyridyl)imidazole
- (11) 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)-imidazole
- (12) 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
- 15
- (13) 2-(4-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
- (14) 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
- (15) 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
- 20
- (16) 4-(3-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole
- (17) 4-(2-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole
- (18) 2-(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole
- (19) 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4-pyridyl)imidazole
- 25
- (20) 4-(4-benzyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole.

For the purposes herein of nomenclature, the compounds of formula I are named by their position corresponding to:



- 13 -

The invention is described herein in detail using the terms defined below unless otherwise specified.

"Halogen" includes fluorine, chlorine, bromine and iodine.

The term "alkyl" refers to a monovalent alkane

- 5 (hydrocarbon)-derived radical containing the designated number of carbon atoms. It may be straight or branched. Examples include methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, sec-butyl, isopentyl and t-butyl.

- 10 The term "alkenyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) carbon-carbon double bonds may be present. Examples of alkenyl groups include ethenyl, propenyl, butenyl and isobutenyl.

- 15 The term "alkynyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Examples of alkynyl groups include ethynyl, propynyl and butynyl.

- 20 Aryl refers to aromatic rings including phenyl and naphthyl.

- The term "heteroaryl" (on its own or in any combination, such as "heteroaryloxy") represents a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O and S, such as, but not limited to pyridyl, pyrimidinyl, 25 pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, triazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl, benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, 2,3-dihydrobenzofuranyl, quinolinyl, isoquinolinyl, benzotriazolyl, 30 benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, purinyl, furopyridine and thienopyridine, tetrahydrobenzothiazolyl, 5,6,7,8-tetrahydroquinolinyl, 2,3-cyclopentenopyridyl, 4,5,6,7-tetrahydroindolyl, 5,6,7,8-tetrahydroisoquinolyl, and 5,6,7,8-tetrahydroquinoxalyl.

- 14 -

"Heterocyclic" (on its own or in any combination, such as "heterocyclalkyl") represents a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O and S. Examples
5 of heterocycls are piperidinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroimidazo[4,5-c]pyridine, imidazoliny, piperazinyl, pyrazolindinyl and the like.

The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s),
10 and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the
15 pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may occur as racemates,
20 racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included within the scope of the present invention.

Throughout the instant application, the following abbreviations are used with the following meanings:

25	Bu	butyl
	Bn	benzyl
	BOC, Boc	t-butyloxycarbonyl
	BOP	Benzotriazol-1-yloxy tris(dimethylamino)- phosphonium hexafluorophosphate
30	CBZ, Cbz	Benzyloxycarbonyl
	DCC	Dicyclohexylcarbodiimide
	DCM	dichloromethane
	DIEA	diisopropylethylamine
	DMF	N,N-dimethylformamide

- 15 -

	DMAP	4-Dimethylaminopyridine
	DSC	N,N'-disuccinimidyl carbonate
	DTT	dithiothreitol
5	EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	Et	ethyl
	EtOAc	ethyl acetate
	EtOH	ethanol
	eq.	equivalent(s)
10	FAB-MS	Fast atom bombardment-mass spectroscopy
	HOAc	acetic acid
	HPLC	High pressure liquid chromatography
	HOBT, HOBt	Hydroxybenztriazole
	H	human serum
15	KHMDS	Potassium bis(trimethylsilyl)amide
	LAH	Lithium aluminum hydride
	LHMDS	Lithium bis(trimethylsilyl)amide
	Me	methyl
	MHz	Megahertz
20	MPLC	Medium pressure liquid chromatography
	NMM	N-Methylmorpholine
	NMR	Nuclear Magnetic Resonance
	PBS	phosphate buffer saline
	Ph	phenyl
25	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
	TLC	Thin layer chromatography
	TMS	Tetramethylsilane

30 The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids/bases and organic acids/bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous,

- 16 -

potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted
5 amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine,
10 hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

Salts derived from inorganic acids include hydrochloric,
15 hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids include acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

20 The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming
25 inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

This invention relates to a method of inhibiting the action of glucagon at its receptors thereby reducing the rate of gluconeogenesis and the concentration of glucose in plasma. Thus,
30 compounds of formula I can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon. Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.

- 17 -

The compounds of formula I are normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. This invention, therefore, also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier employed may be, for example, solid or liquid. Solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier may include time delay material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.

The compounds of formula I are administered in conventional dosage forms prepared by combining a compound of formula I with standard pharmaceutical carriers according to conventional procedures. The compounds of formula I may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incorporated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.

- 18 -

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally, for example intravenously, intramuscularly, intradermally or subcutaneously. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

The compounds of formula I may also be administered topically in the form of a liquid, solid or semi-solid. Liquids include

- 19 -

solutions, suspensions and emulsions. Solids include powders, poultices and the like. Semi-solids include creams, ointments, gels and the like.

Drops according to the present invention may comprise sterile aqueous or oil solutions or suspensions, and may be prepared by
5 dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a
10 sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis
15 oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an
20 aqueous or non-aqueous liquid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as steric or oleic
25 acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and
30 other ingredients such as lanolin may also be included.

Compounds of the present invention may also be administered intranasally as, for example, liquid drops or spray; by intranasal or oral inhalation; rectally; trasdermally; or vaginally.

- 20 -

The amount of a compound of formula I, for the methods of use disclosed herein, vary with the compound chosen, the mode of administration, the nature and severity of the condition being treated, and other factors left to the discretion of the physician. A representative
5 dosing regimen for treating diabetes mellitus and/or hyperglycemia may involve administering a compound of formula I at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult
10 human, the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

Compounds similar to Formula I have been described previously as cytokine inhibitors (WO93/14081; WO95/03297),
15 antiinflammatory agents (WO96/03387), and protein kinase inhibitors (WO96/18626). None of these publications describe or claim treatment of diabetes by antagonism of the glucagon receptor by compounds of Formula I.


Compounds of the present invention may be prepared by
20 several general synthetic methods as described in, for example, M. R. Grimmett, *Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds*, A. R. Katritzky and C. W. Rees, eds., Vol. 5, Pergamon Press, Oxford, 1984, pp. 457-498. The compounds of the present invention can be prepared by
25 procedures illustrated in the accompanying schemes. The three general methods for preparation of the imidazole nucleus are outlined in Schemes 1 and 2.

In the first method (Scheme 1), a suitably protected alcohol
(1) (e.g., when R₁ is 4-pyridyl, (1) is
30 4-(t-butyldimethylsilyloxymethyl)pyridine), is deprotonated with a strong base such as lithium diisopropyl amide or n-butyl lithium and the resulting anion is reacted with an appropriate N,O-dimethylhydroxamide (2) to give a protected α -hydroxy ketone (3). The protected α -hydroxy ketone is then condensed with a suitably functionalized aldehyde (4) in

- 21 -

the presence of copper(II) acetate and ammonium acetate in acetic acid to form the desired compound (5).

Scheme 1.




5

In the second method (Scheme 2), an heteroarylmethane (6) (e.g., when R_1 is 4-pyridyl, (6) is 4-picoline) is deprotonated with a strong base such as lithium diisopropyl amide or n-butyl lithium and the resulting anion is reacted with N,O-dimethylhydroxamide (2) to give a ketone (7). The dione (8) is obtained by selenium dioxide oxidation of the ketone (7) and then condensed with a suitably functionalized aldehyde (4) in the presence of ammonium acetate in acetic acid to form the desired imidazole (5).

10

Scheme 2.




In the various synthetic methods described above, protection and deprotection of functional groups such as hydroxyl and amino groups may be required. The selection of the appropriate protecting groups, and methods for introducing and removing the protecting groups are within the knowledge of one skilled in the art, and are also described in standard reference books such as Greene and Wuts, Protective Groups in Organic Synthesis, 2d Ed., John Wiley & Sons, Inc., 1991.

The following examples are provided to more fully illustrate the invention, and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLE 1

4-(4-t-Butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole

- 23 -



Step A. 4-(t-Butyldimethylsilyloxy)methyl pyridine

At room temperature, 10.9 g of 4-pyridylcarbinol (100 mmol) was
5 treated with 60 mL of DCM followed by 21 mL (150 mmol) of triethylamine.
After being cooled to 10 °C, 18 g (120 mmol) of t-butyldimethylsilyl chloride
(dissolved in 20 mL DCM) was added dropwise. The resulting reaction
mixture was warmed to room temperature slowly and stirred overnight.
Subsequently, it was filtered over a pad of celite, rinsed with ether. Volatiles
10 were removed and the residue was taken up in hexane and filtered over celite
again, washed with hexane/ether, and the solvents removed by rotoevaporation.
This was repeated twice. Pumping under high vac of the residue thus obtained
provided 22 g (99%) of the desired product as a light brown oil, mass spectrum
(CI) m/e = 224 (M+1)⁺.

15

Step B. 4-Pyridyl-t-butyldimethylsilyloxymethyl 4-fluorophenyl ketone

Into a 2 L 3-necked round bottom flask fitted with a thermometer,
dry nitrogen gas inlet, addition funnel and mechanical stirrer was added
diisopropylamine (65 mL, 0.46 mol) in THF (120 mL). Cooled to -20 °C with
20 a isopropyl alcohol/ dry ice bath and added a solution of n-butyllithium in
hexanes (210 mL of a 2.5 M solution, 0.53 mol). Stirred at -15 °C for 30 min,
then cooled to -20 °C. Added 4-t-butyldimethylsilyloxymethylpyridine from
Step A (98.2 g, 0.44 mol) neat over a 30 min period. Let stir for 45 min at -20
°C. To this mixture was added a solution of 4-fluoro-N-methoxy-N-methyl-
25 benzamide (84.5 g, 0.46 mol) in THF (90 mL) over a 30 min period. The dark
solution was stirred at 0 °C for 1 h, then warmed slowly to room temperature
for 30 min. The reaction was poured into water (500 mL) containing
ammonium chloride (100 g). After stirring for 10 min at room temperature, the

- 24 -

solution was extracted with ethyl acetate (3 times). The combined organic extracts were washed successively with water and saturated salt solution. The combined aqueous layers were extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 15-50% ethyl acetate in hexanes (17 L in total). The solvent was removed by rotoevaporation to yield the title compound as an amber oil (120.4 g, 74% yield).

10

Step C: 4-Pyridyl-t-butydimethylsilyloxymethyl 4-t-butylphenyl ketone

To a cooled solution of diisopropylamine (183 mg, 1.81 mmol) in dry THF (0.35 mL) at -20 °C was added a solution of n-butyllithium in hexanes (0.83 mL of a 2.5 M solution, 2.08 mmol). Stirred at -20 °C for 1 hr and then added a solution of 4-pyridyl-t-butydimethylsilyloxymethyl 4-fluorophenyl ketone from Step B (383 mg, 1.72 mmol) in THF (0.45 mL). Stirred at -20 °C for 45 min, resulting in a thick yellow-brown solution. A solution of 4-t-butyl-N-methoxy-N-methyl-benzamide (400 mg, 1.81 mmol) in THF (0.5 mL) was added and the solution stirred at -20 to 0 °C for 5 h. The reaction was cooled to -20 °C and quenched by the addition of a saturated ammonium chloride solution. The reaction mixture was then extracted with ethyl acetate (3 times) and the combined extracts washed successively with water (2 times) and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 5-10% ethyl acetate in hexanes to yield the title compound as a yellow oil (341 mg, 49% yield).

Step D: 4-(4-t-Butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole

A solution of 4-pyridyl-t-butydimethylsilyloxymethyl 4-t-butylphenyl ketone from Step C (170 mg, 0.44 mmol), copper (II) acetate (161 mg, 0.89 mmol), ammonium acetate (342 mg, 4.44 mmol) and 4-chlorobenzaldehyde (78 mg, 0.56 mmol) in acetic acid (3 mL) was heated to 110 °C for 5 h. The reaction mixture was then cooled to 0 °C and ice (4 g),

35

- 25 -

ethyl acetate (4 mL) and concentrated ammonium hydroxide solution (4 mL) were added. After stirring for 30 min, the phases were separated and the aqueous layer extracted with ethyl acetate (2 times). The combined organic phases were successively washed with water (2 times) and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-3% methanol in methylene chloride to yield the title compound as a pale yellow solid 102 mg, 59% yield), mass spectrum (CI) $m/e = 388 (M+1)^+$.

The following compounds were prepared by methods analogous to those described in Example 1 except the appropriately substituted N-methoxy-N-methylbenzamide and substituted benzaldehyde was used in place of 4-t-butyl-N-methoxy-N-methylbenzamide and 4-chlorobenzaldehyde, respectively.

2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 424 (M+1)^+$.

2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 424 (M+1)^+$.

2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 458 (M+1)^+$.

2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 482 (M+1)^+$.

4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 388 (M+1)^+$.


4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 388 (M+1)^+$.

- 26 -

- 4-(4-t-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 388 (M+1)^+$.
- 5 2-(4-chlorophenyl)-4-(4-n-propyloxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 390 (M+1)^+$.
- 2-(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 392 (M+1)^+$.
- 10 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)-imidazole, mass spectrum (CI) $m/e = 458 (M+1)^+$.
- 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 468, 470 (M+1)^+$.
- 15 2-(4-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 408 (M+1)^+$.
- 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 496 (M+1)^+$.
- 20 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 408 (M+1)^+$.
- 4-(3-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 404 (M+1)^+$.
- 25 4-(2-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 404 (M+1)^+$.
- 30 4-(4-benzyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 438 (M+1)^+$.

EXAMPLE 2

- 27 -

2-(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole

5

Step A: 2,4-dihydroxy-N-methoxy-N-methyl-benzamide

To a cooled solution of 2,4-dihydroxybenzoic acid (8 g, 52 mmol), N,O-dimethylhydroxylamine hydrochloride (6.1 g, 62 mmol) and N-methylmorpholine (13.18 g, 130 mmol) in methylene chloride (50 mL) at 0 °C was added EDC batchwise (11.95 g, 62.3 mmol). Stirred at room temperature for 3 days. The reaction was quenched by the addition of water and then extracted with methylene chloride (2 times). The combined organic extracts were successively washed with a 10% aqueous citric acid solution, a 5% sodium bicarbonate solution, water and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-33% ethyl acetate in hexanes to yield the title compound, mass spectrum (CI) $m/e = 198 (M+1)^+$.

20 Step B: 2,4-Di-n-propyloxy-N-methoxy-N-methyl-benzamide

To a solution of 2,4-dihydroxy-N-methoxy-N-methyl-benzamide (250 mg, 1.27 mmol) in DMF (1 mL) was added solid potassium carbonate (351 mg, 2.54 mmol) and 1-bromopropane (343 mg, 2.79 mmol). The reaction mixture was stirred overnight at 55 °C. The reaction was quenched by the addition of an aqueous solution of 10% citric acid. The mixture was extracted with ethyl acetate (2 times). The combined organic extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted

- 28 -

with 0-50% ethyl acetate in hexanes to give the title compound, mass spectrum (CI) $m/e = 282 (M+1)^+$.

Step C: 2,4-Di-n-propyloxyphenyl 4-pyridylmethyl ketone

5 To a cooled solution of lithium diisopropylamide (generated from diisopropylamine (109 mg, 1.07 mmol) and a solution of n-butyllithium in hexanes (0.49 mL of a 2.5 M solution, 1.22 mmol)) in THF (0.5 mL) at -78 °C was added 4-picoline (95 µL, 0.98 mmol). Stirred -78 to 0 °C for 1 h. The reaction mixture was cooled to -78 °C and a solution of 2,4-di-n-propyloxy-N-methoxy-N-methyl-benzamide from Step B (274 mg, 0.98 mmol) in THF (0.5 mL) was added dropwise. The reaction was stirred < 0 °C for 4 h and then quenched by the addition of a saturated aqueous solution of ammonium chloride. The mixture was extracted with ethyl acetate (2 times). The combined extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The solution was filtered and the solvents removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-50% ethyl acetate in hexanes to yield the title compound (147 mg, 48% yield), mass spectrum (CI) $m/e = 314 (M+1)^+$.

20

Step D: 1-(2,4-Di-n-propyloxyphenyl)-2-(4-pyridyl)ethane-1,2-dione

To an oxygen-free solution of 2,4-di-n-propyloxyphenyl 4-pyridylmethyl ketone (142 mg, 0.45 mmol) in acetic acid (3.4 mL) was added selenium dioxide (50.3 mg, 0.45 mmol). The reaction was stirred at 90 °C for 1 h, then cooled to 0 °C. The reaction was quenched by the addition of a solution of potassium carbonate until the pH = 8. The mixture was then extracted with ethyl acetate (2 times) and the combined extracts successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The solution was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 50% ethyl acetate in hexanes to yield the title compound as a sticky yellow gum (65 mg, 44% yield), mass spectrum (CI) $m/e = 328 (M+1)^+$.

30

- 29 -

Step E: 2-(4-Chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole

A solution of 1-(2,4-di-n-propyloxyphenyl)-2-(4-pyridyl)ethane-1,2-dione from Step D (61 mg, 0.19 mmol), ammonium acetate (144 mg, 1.87 mmol) and 4-chlorobenzaldehyde (33 mg, 0.23 mmol) in acetic acid (1.5 mL) was heated to 100 °C for 3.5 h. After cooling to 0 °C, the ice (4g), ethyl acetate (2 mL) and a concentrated solution of ammonium hydroxide was added until the pH was 10. The layers were separated and the aqueous layer extracted with ethyl acetate. The combined organic extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-3% methanol in methylene chloride to yield the title compound as a cream-colored solid (25 mg, 30% yield), mass spectrum (CI) $m/e = 448 (M+1)^+$.

The following compound was prepared by methods analogous to those described in Example 1 except in Step B, 1-bromobutane was substituted for 1-bromopropane:

20 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) $m/e = 476 (M+1)^+$.

BIOLOGICAL ASSAYS

25 The ability of compounds of the present invention to inhibit the binding of glucagon and the synthesis or the activity of cytokines can be determined by the following *in vitro* assays.

¹²⁵I-Glucagon Binding Screen with CHO/hGLUR Cells

The reagents are prepared as follows:

30 1M o-Phenanthroline (Aldrich #32,005-6, MW 198.23)(prepare fresh): 198.2 mg/ml ethanol

0.5M DTT (Sigma #D-9779, MW 154.2) (prepare fresh).

- 30 -

Protease Inhibitor Mix(1000X): 5 mg leupeptin + 10 mg benzamidine + 40 mg bacitracin + 5 mg soybean trypsin inhibitor per ml DMSO. Store aliquots at -20 °C.

5

250 µM Human Glucagon (Peninsula #7165, MW 3480.62): Solubilize 0.5 mg vial in 575 µl 0.1N acetic acid. Store in aliquots at -20 °C. Thus, 1 µl yields 1 µM final concentration in assay for non-specific binding.

- 10 Assay Buffer: 20 mM Tris, pH 7.8; 1 mM DTT; 3 mM o-phenanthroline.

Assay Buffer w/ 0.1% BSA (for dilution of label only, therefore 0.01% final in assay): 10 µl 10% BSA (heat-inactivated) + 990 µl assay buffer

- 15 ¹²⁵I-Glucagon (NEN #NEX-207, receptor-grade, 2200 Ci/mmol): Dilute to 50,000 cpm/25 µl in assay buffer w/ BSA. Thus, ~50 pM final concentration in assay.

Harvesting of CHO/hGLUR Cells for Assay:

- 20 1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for ~4 min. at 37 °C.
- 25 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in assay buffer (no BSA) at 75000 cells per 100 µl.

- Alternatively, membrane preparations from CHO/hGLUR
- 30 cells can be used in place of whole cells at the same assay volume. Final protein concentration of membrane preparation is determined on a per batch basis.

- 31 -

The determination of inhibition of glucagon binding is carried out by measuring the reduction of ^{125}I -glucagon binding in the presence of compounds of Formula I. The assay is carried out in a 96-well box. The following reagents are combined:

5		<u>Assay</u> <u>Buffer</u>	<u>Compound</u> <u>/Vehicle</u>	<u>250 μM</u> <u>Glucagon</u>	<u>125I-</u> <u>Glucagon</u>	<u>CHO/hGLUR</u> <u>Cells</u>
10	Total Binding	120 μ L	--/5 μ L	--	25 μ L	100 μ L
	+compound	120 μ L	5 μ L/--	--	25 μ L	100 μ L
	NSB	120 μ L	--/5 μ L	1 μ L	25 μ L	100 μ L


NSB:non specific binding

The box is incubated for 60 min. at 22 °C on a shaker at 275 rpm. The wells are filtered over pre-soaked (0.5% polyethylimine(PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20 mM Tris, pH 7.8 buffer. Count filters in Gamma-scintillation counter.

- 32 -

WHAT IS CLAIMED IS:

1. A compound having the formula (I)



5

wherein

- R₁ is 4-pyridyl, 4-pyrimidinyl or 4-quinolyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
- (1) halogen,
 - (2) -CN,
 - (3) C₁₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (4) -O-C₁₋₁₀ alkyl,
 - (5) -S-C₁₋₁₀ alkyl,
 - (6) -NR₈R₉, and
 - (7) -NO₂;

15

- R₂ is phenyl, 1-naphthyl, 2-naphthyl or heteroaryl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of
- (1) C₁₋₁₀ alkyl,
 - (2) R₄, and
 - (3) C₁₋₁₀ alkyl substituted with up to 5 groups independently selected from R₄;

20

25

R₃ is phenyl, which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

30

- (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,

- 33 -

- 5
- 0(2) -O-C₃₋₁₀ alkyl,
 (3) -O-C₁₋₄ alkylaryl,
 (4) -S-C₂₋₁₀ alkyl,
 (5) -S(O)_mC₃₋₁₀ alkyl,
 (6) -C(O)C₃₋₁₀ alkyl,
 (7) -CO₂C₃₋₁₀ alkyl,
 (8) -NR₇R₁₇,
 (9) *meta* -O-phenyl, which is optionally substituted with halo,
 C₁₋₄ alkyl, or C₁₋₄ alkoxy;
- 10 R₄ is
- 15
- (1) -OR₈,
 (2) -NO₂,
 (3) halogen
 (4) -S(O)_mR₁₁,
 (5) -SR₈,
 (6) -S(O)_mOR₈,
 (7) -S(O)_mNR₈R₉,
 (8) -NR₈R₉,
 (9) -O(CR₁₀R₂₀)_pNR₈R₉,
- 20
- (10) -C(O)R₈,
 (11) -CO₂R₈,
 (12) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
 (13) -ZC(O)R₈,
 (14) -CN,
- 25
- (15) -C(Z)NR₈R₉,
 (16) NR₁₀C(Z)R₈,
 (17) -C(Z)NR₈OR₉,
 (18) NR₁₀C(Z)NR₈R₉,
 (19) -NR₁₀S(O)_mR₁₁,
- 30
- (20) -C(=NOR₂₁)R₈,
 (21) -NR₁₀C(=NR₁₅)SR₁₁,
 (22) -NR₁₀C(=NR₁₅)NR₈R₉,
 (23) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
 (24) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,

- 34 -

- (25) $-\text{NR}_{10}\text{C}(\text{O})\text{C}(\text{O})\text{NR}_8\text{R}_9$,
 (26) $-\text{NR}_{10}\text{C}(\text{O})\text{C}(\text{O})\text{OR}_{10}$,
 (27) $-\text{C}(=\text{NR}_{13})\text{NR}_8\text{R}_9$,
 (28) $-\text{C}(=\text{NOR}_{13})\text{NR}_8\text{R}_9$,
 5 (29) $-\text{C}(=\text{NR}_{13})\text{ZR}_{11}$,
 (30) $-\text{OC}(\text{Z})\text{NR}_8\text{R}_9$,
 (31) $-\text{NR}_{10}\text{S}(\text{O})_m\text{CF}_3$,
 (32) $-\text{NR}_{10}\text{C}(\text{Z})\text{OR}_{10}$,
 (33) 5-(R₁₈)-1,2,4-oxadiazol-3-yl or
 10 (34) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl;
 R₇ and R₁₇ are each independently selected from hydrogen or C₁₋₄ alkyl
 provided that R₇ and R₁₇ are not both hydrogen; or R₇ and R₁₇
 together with the nitrogen to which they are attached form a
 heterocyclic ring of 5 to 7 members which ring optionally
 15 contains an additional heteroatom selected from oxygen, sulfur or
 NR₂₂;
 R₈ and R₉ are independently selected from
 (1) hydrogen,
 (2) heterocyclyl,
 20 (3) heterocyclyl-C₁₋₁₀ alkyl, and
 (4) R₁₁; or
 R₈ and R₉ together with the nitrogen to which they are attached form a
 heterocyclic ring of 5 to 7 members which ring optionally
 contains an additional heteroatom selected from oxygen, sulfur or
 25 NR₁₂;
 R₁₀ and R₂₀ is each independently selected from hydrogen or C₁₋₄ alkyl;
 R₁₁ is
 (1) C₁₋₁₀ alkyl,
 (2) halo-substituted C₁₋₁₀ alkyl,
 (3) C₂₋₁₀ alkenyl,
 30 (4) C₂₋₁₀ alkynyl,
 (5) C₃₋₇ cycloalkyl,
 (6) C₅₋₇ cycloalkenyl,
 (7) aryl,
 (8) aryl-C₁₋₁₀ alkyl,

- 35 -

- (9) heteroaryl or
 (10) heteroaryl-C₁₋₁₀ alkyl;
 R₁₂ is (1) hydrogen,
 (2) -C(Z)R₁₃,
 5 (3) optionally substituted C₁₋₄ alkyl,
 (4) optionally substituted aryl C₁₋₄ alkyl, or
 (5) S(O)₂R₂₅;
 R₁₃ is (1) hydrogen, or
 (2) R₂₅;
 10 R₁₄ and R₂₄ is each independently selected from
 (1) hydrogen,
 (2) C₁₋₄ alkyl,
 (3) nitro or
 (4) cyano;
 15 R₁₅ is (1) hydrogen,
 (2) cyano,
 (3) C₁₋₄ alkyl,
 (4) C₃₋₇ cycloalkyl or
 (5) aryl;
 20 R₁₈ and R₁₉ is each independently selected from
 (1) hydrogen,
 (2) C₁₋₄ alkyl,
 (3) substituted C₁₋₄ alkyl,
 (4) optionally substituted aryl,
 25 (5) optionally substituted aryl-C₁₋₁₀ alkyl or
 R₁₈ and R₁₉ together denote an oxo or thioxo;
 R₂₁ is (1) R₁₃,
 (2) a pharmaceutically acceptable cation, or
 (3) aroyl, or
 30 (4) C₁₋₁₀ alkanoyl;
 R₂₂ is R₁₀ or C(Z)-C₁₋₄ alkyl;
 R₂₅ is (1) C₁₋₁₀ alkyl,
 (2) C₃₋₇ cycloalkyl,
 (3) heterocyclyl,

- 36 -

- (4) aryl,
(5) aryl C₁₋₁₀ alkyl,
(6) heterocyclyl-C₁₋₁₀ alkyl,
(7) heteroaryl or
5 (8) heteroaryl C₁₋₁₀ alkyl;
Z is .oxygen or sulfur;
m is 1 or 2;
n is 1 to 10;
p is 1 to 10; or
10 a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1

wherein

- R₁ is 4-pyridyl which is unsubstituted or substituted with one or two
15 substituents each of which is independently selected from the
group consisting of
(1) halogen,
(2) -CN,
(3) C₁₋₁₀ alkyl, wherein said alkyl is optionally
20 substituted with from 1 to 5 halogen atoms,
(4) -O-C₁₋₁₀ alkyl,
(5) -S-C₁₋₁₀ alkyl,
(6) -NR₈R₉, and
(7) -NO₂.

25 3. A compound of Claim 1

wherein

- R₂ is phenyl, 1-naphthyl or 2-naphthyl each of which is unsubstituted or
substituted with one, two or three groups each of which is
30 independently selected from the group consisting of
(1) C₁₋₁₀ alkyl,
(2) R₄, and
(3) C₁₋₁₀ alkyl substituted with up to 5 groups
independently selected from R₄.

- 37 -

4. A compound of Claim 1
wherein
R₃ is phenyl, which is unsubstituted or substituted with one or two substituents
5 each of which is independently selected from the group
consisting of
(1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted
with from 1 to 5 halogen atoms,
(2) -O-C₃₋₁₀ alkyl,
10 (3) -O-C₁₋₄ alkylaryl,
(4) -S-C₂₋₁₀ alkyl,
(5) *meta* -O-phenyl, which is optionally substituted with halo,
C₁₋₄ alkyl, or C₁₋₄ alkoxy;
- 15 5. A compound of Claim 1
wherein
R₁ is 4-pyridyl or 4-quinolyl;
R₂ is phenyl which is unsubstituted or substituted with one, two or three
substituents each of which is independently selected from the
20 group consisting of
(1) C₁₋₁₀ alkyl,
(2) R₄, and
(3) C₁₋₁₀ alkyl substituted with up to 5 groups
independently selected from R₄;
25 R₃ is phenyl substituted with one or two substituents each of which is
independently selected from the group consisting of
(1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted
with from 1 to 5 halogen atoms,
(2) -O-C₃₋₁₀ alkyl,
30 (3) -O-C₁₋₂ alkylaryl,
(4) -S-C₂₋₁₀ alkyl,
(5) *meta* -O-phenyl, which is optionally substituted with halo,
C₁₋₄ alkyl, or C₁₋₄ alkoxy;
R₄ is

- 38 -

- (1) -OR₈,
 (2) halogen
 R₈ is selected from
 (1) hydrogen, and
 (2) R₁₁; and
 R₁₁ is
 (1) C₁₋₁₀ alkyl,
 (2) halo-substituted C₁₋₁₀ alkyl,
 (3) C₃₋₇ cycloalkyl,
 (4) aryl,
 (5) aryl-C₁₋₁₀ alkyl, or
 a pharmaceutically acceptable salt thereof.

6. A compound of Claim 1
 wherein
 R₁ is 4-pyridyl;
 R₂ is phenyl which is substituted with one or two substituents each of which is
 independently selected from the group consisting of
 (1) C₁₋₁₀ alkyl,
 (2) R₄, and
 (3) C₁₋₁₀ alkyl substituted with up to 5 groups
 independently selected from halogen
 R₃ is phenyl substituted with one or two substituents each of which is
 independently selected from the group consisting of
 (1) C₄₋₁₀ alkyl, wherein said alkyl is optionally substituted
 with from 1 to 5 halogen atoms,
 (2) -O-C₃₋₁₀ alkyl,
 (3) -O-C₁₋₂ alkylaryl,
 (4) -S-C₂₋₁₀ alkyl,
 (5) *meta* -O-phenyl, which is optionally substituted with halo,
 C₁₋₄ alkyl, or C₁₋₄ alkoxy;
 R₄ is
 (1) -OR₈,
 (2) halogen;
 R₈ is R₁₁;

- 39 -

- R₁₁ is
- (1) C₁₋₁₀ alkyl,
 - (2) halo-substituted C₁₋₁₀ alkyl,
 - (3) C₃₋₇ cycloalkyl,
 - (4) aryl,
 - 5 (5) aryl-C₁₋₁₀ alkyl, or
- a pharmaceutically acceptable salt thereof.

7. A compound of Claim 1 selected from the group consisting of:
- 10 (1) 2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 - (2) 2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 - (3) 2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 - 15 (4) 2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 - (5) 4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
 - 20 (6) 4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
 - (7) 4-(4-t-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
 - (8) 4-(4-t-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
 - 25 (9) 2-(4-chlorophenyl)-4-(4-n-propyloxyphenyl)-5-(4-pyridyl)imidazole,
 - (10) 2-(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4-pyridyl)imidazole,
 - 30 (11) 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)-imidazole,
 - (12) 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,

- 40 -

- (13) 2-(4-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole
- (14) 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
- 5 (15) 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
- (16) 2-(4-chlorophenyl)-4-(3-n-butyloxyphenyl)-5-(4-pyridyl)imidazole,
- (17) 2-(4-chlorophenyl)-4-(2-n-butyloxyphenyl)-5-(4-pyridyl)imidazole,
- 10 (18) 2-(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole,
- (19) 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4-pyridyl)imidazole, and
- 15 (20) 2-(4-chlorophenyl)-4-(4-benzyloxyphenyl)-5-(4-pyridyl)imidazole.


8. A method of treating glucagon mediated disease in a mammal in need of such treatment, which comprises administering to
20 said mammal an effective amount of a glucagon antagonist.

9. A method of treating diabetes disease in a mammal in need of such treatment, which comprises administering to said mammal an effective amount of a glucagon antagonist of Claim 1.

25 10. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/21020

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/44; C07D 401/00 US CL :514/341; 546/278 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/341; 546/278 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,772,441 A (LOMBARDINO) 13 November 1973, see column 10, lines 49 and 54 and column 11, line 16.	1-3, 4 and 9
Y, P	US 5,686,455 A (ADAMS et al.) 11 November 1997, see column 6, lines 29-44.	1-6 and 9
A, P	US 5,620,999 A (WEIER et al.) 15 April 1997.	1-9
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* *A* *E* *L* *O* *P*	Special categories of cited documents document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *&* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date of the actual completion of the international search 12 JANUARY 1998		Date of mailing of the international search report 10 FEB 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  RAYMOND J. HENLEY III Telephone No. (703) 308-1235